양한나 (차의과학대학교 분당차병원)님 | 한빛사연구자 > 한빛사

차의과학대학교 분당차병원

CV File

종양의학

최종업데이트 2023.07.03.

Systemic Delivery of a STING Agonist-Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis
- Small, 2023 Jun 28;e2300544 | https://doi.org/10.1002/smll.202300544
- 2023-06
- 의약학
- 한빛사논문
Thyroid Dysfunction After Atezolizumab and Bevacizumab is Associated with Favorable Outcomes in Hepatocellular Carcinoma
- Liver Cancer, MAY 25 2023 | DOI: 10.1159/000531182
- 2023-05
- 의약학
- 한빛사논문
High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma-Reply
- JAMA Oncol., 2023 Mar 16 | doi: 10.1001/jamaoncol.2023.0111
- 2023-03
- 의약학
- 한빛사논문
Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma
- JAMA Oncol., Published online October 20, 2022 | doi:10.1001/jamaoncol.2022.4733
- 2022-10
- 의약학
- 한빛사논문
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity
- Exp. Mol. Med., Published 11 September 2020 | https://doi.org/10.1038/s12276-020-00500-y
- 2020-09
- 의약학
- 상위피인용논문
STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer
- J. Immunother. Cancer, Online issue publication June 18, 2021, 9: e002195 | http://dx.doi.org/10.1136/jitc-2020-002195
- 2021-06
- 의약학
- 한빛사논문
STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade
- J. Clin. Invest., published July 25, 2019 | https://doi.org/10.1172/JCI125413
- 2019-07
- 의약학
- 한빛사논문

연구자 ID

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기